AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 8428859 — intervention group
Group type: EXPERIMENTAL
Intervention: Open continuous nebulization (ON)
Number of subjects: 21
Study 8428859 — intervention group
Group type: COMPARATOR
Intervention: Oral route (OR)
Number of subjects: 21
Study 3313099 — intervention group
Group type: EXPERIMENTAL
Intervention: L-baclofen
Number of subjects: 15
Study 3313099 — intervention group
Group type: COMPARATOR
Intervention: racemic baclofen
Number of subjects: 15
Study 29707864 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-MOT training
Number of subjects: 0
Study 29707864 — intervention group
Group type: COMPARATOR
Intervention: Visual strategy/math-based game (2048)
Number of subjects: 0
Study 29707864 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 0
Study 27006332 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160mg) once daily
Number of subjects: 1717
Study 27006332 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1717
Study 24941010 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of insulin and glucose, titrated to preserve normoglycemia (3.5‐6.1 mmol L(‐1))
Number of subjects: 26
Study 24941010 — intervention group
Group type: COMPARATOR
Intervention: Standard metabolic care (blood glucose 3.5‐10 mmol L(‐1))
Number of subjects: 26
Study 23225820 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure drainage group (n=32)
Number of subjects: 62
Study 23225820 — intervention group
Group type: COMPARATOR
Intervention: Natural drainage group (n=30)
Number of subjects: 62
Study 21575130 — intervention group
Group type: EXPERIMENTAL
Intervention: N7-GP (dose of 12.5-100 μg kg(‐1))
Number of subjects: 40
Study 18313674 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation for 3 months
Number of subjects: 70
Study 16504397 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cortisol (30 mg)
Number of subjects: 31
Study 16504397 — intervention group
Group type: COMPARATOR
Intervention: Relaxed test situation
Number of subjects: 31
Study 12946546 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen fumarate 0.025% ophthalmic solution
Number of subjects: 59
Study 12946546 — intervention group
Group type: EXPERIMENTAL
Intervention: Nedocromil sodium 2.0% ophthalmic solution
Number of subjects: 59
Study 12946546 — intervention group
Group type: COMPARATOR
Intervention: Placebo (artificial tears)
Number of subjects: 59
Study 12946546 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall eyedrop preference
Number of subjects: 59
Study 10983647 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T + ddI + IDV
Number of subjects: 205
Study 10983647 — intervention group
Group type: COMPARATOR
Intervention: ZDV + 3TC + IDV
Number of subjects: 205
Study 10983647 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T
Number of subjects: 205
Study 10983647 — intervention group
Group type: COMPARATOR
Intervention: ZDV
Number of subjects: 205
Study 9108190 — intervention group
Group type: EXPERIMENTAL
Intervention: Pefloxacin
Number of subjects: 14
Study 9108190 — intervention group
Group type: COMPARATOR
Intervention: Norfloxacin
Number of subjects: 14
Study 8403154 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 100 mg
Number of subjects: 48
Study 8403154 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-Chloroprocaine 100 mg
Number of subjects: 48
Study 8403154 — intervention group
Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 48
Study 3437302 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonazepam (0.5-2 mg per night)
Number of subjects: 20
Study 3437302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 29206813 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg, t.i.d)
Number of subjects: 20
Study 27881136 — intervention group
Group type: EXPERIMENTAL
Intervention: CHWs trained to use rapid diagnostic tests (RDTs) for malaria diagnosis
Number of subjects: 0
Study 27881136 — intervention group
Group type: COMPARATOR
Intervention: CHWs using presumptive diagnosis based on clinical signs and symptoms
Number of subjects: 0
Study 27881136 — intervention group
Group type: EXPERIMENTAL
Intervention: CHWs prescribed artemisinin-based combination therapy (ACT)
Number of subjects: 0
Study 27881136 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-referral treatment with rectal artesunate
Number of subjects: 0
Study 25011077 — intervention group
Group type: EXPERIMENTAL
Intervention: Principal Component Analysis (PCA) applied to 19 inflammatory biomarkers
Number of subjects: 0
Study 22782366 — intervention group
Group type: EXPERIMENTAL
Intervention: Lightweight mesh (LW)
Number of subjects: 0
Study 22782366 — intervention group
Group type: COMPARATOR
Intervention: Heavyweight mesh (HW)
Number of subjects: 0
Study 22782366 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study 15950945 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-lipoic acid (LA) supplementation
Number of subjects: 0
Study 12032519 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4)
Number of subjects: 144
Study 12032519 — intervention group
Group type: EXPERIMENTAL
Intervention: Other tocolytic
Number of subjects: 144
Study 12032519 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 144
Study 12032519 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal serum ionized magnesium levels
Number of subjects: 144
Study 9659136 — intervention group
Group type: EXPERIMENTAL
Intervention: Osteoscan peripheral dual energy X‐ray absorptiometer (pDXA)
Number of subjects: 57
Study 9659136 — intervention group
Group type: COMPARATOR
Intervention: Single photon absorptiometer (SPA)
Number of subjects: 57
Study 9659136 — intervention group
Group type: COMPARATOR
Intervention: Lunar dual energy X-ray absorptiometer (DXA)
Number of subjects: 57
Study 7893296 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketorolac (60 mg)
Number of subjects: 42
Study 7893296 — intervention group
Group type: COMPARATOR
Intervention: Meperidine (75 mg)/Promethazine (25 mg)
Number of subjects: 42
Study 2694346 — intervention group
Group type: EXPERIMENTAL
Intervention: Furazolidone
Number of subjects: 82
Study 2694346 — intervention group
Group type: COMPARATOR
Intervention: Metronidazole
Number of subjects: 82
Study 102008 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole
Number of subjects: 70
Study 102008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gold
Number of subjects: 70
Study 30077530 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive PD treatment (IPT)
Number of subjects: 51
Study 30077530 — intervention group
Group type: COMPARATOR
Intervention: Standard PD treatment (CPT)
Number of subjects: 51
Study 27746332 — intervention group
Group type: COMPARATOR
Intervention: Cemented partial dentures (C-PD, n=35)
Number of subjects: 107
Study 27746332 — intervention group
Group type: COMPARATOR
Intervention: Screwed partial dentures (S-PD, n=35)
Number of subjects: 107
Study 27746332 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-detachable hybrid prostheses (HP, n=37)
Number of subjects: 107
Study 24148695 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity Aerobic Exercise (AE)
Number of subjects: 50
Study 24148695 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity non-aerobic Balance/Flexibility (BF)
Number of subjects: 50
Study 21153699 — intervention group
Group type: EXPERIMENTAL
Intervention: True acupuncture
Number of subjects: 84
Study 21153699 — intervention group
Group type: COMPARATOR
Intervention: Control (CTRL)
Number of subjects: 84
Study 20564351 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained virological response (SVR)
Number of subjects: 180
Study 20564351 — intervention group
Group type: COMPARATOR
Intervention: Virologic nonresponders (NR)
Number of subjects: 180
Study 20564351 — intervention group
Group type: COMPARATOR
Intervention: Breakthrough or relapse (BT/R)
Number of subjects: 180
Study 18498915 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsartan/HCTZ combination therapy
Number of subjects: 1668
Study 18498915 — intervention group
Group type: COMPARATOR
Intervention: Valsartan monotherapy
Number of subjects: 1668
Study 15948086 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled telephone calls by specially trained nurses promoting self‐management and guideline‐based therapy
Number of subjects: 151
Study 15948086 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 151
Study 12013192 — intervention group
Group type: EXPERIMENTAL
Intervention: d-alpha-tocopherol 1,200 I.U. daily
Number of subjects: 45
Study 12013192 — intervention group
Group type: COMPARATOR
Intervention: ascorbic acid 2 g daily
Number of subjects: 45
Study 12013192 — intervention group
Group type: EXPERIMENTAL
Intervention: ascorbic acid 2 g plus d-alpha-tocopherol 1,200 I.U. daily
Number of subjects: 45
Study 10412820 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking mothers (1-50 cigarettes/day)
Number of subjects: 206
Study 10412820 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking mothers (5-50 cigarettes/day)
Number of subjects: 206
Study 10412820 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking mothers (10-50 cigarettes/day)
Number of subjects: 206
Study 10412820 — intervention group
Group type: COMPARATOR
Intervention: Control (nonsmoking parents)
Number of subjects: 206
Study 7772663 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflurane 0.5‐0.8 Vol.% and 70% nitrous oxide in oxygen
Number of subjects: 40
Study 7772663 — intervention group
Group type: COMPARATOR
Intervention: Propofol 1.5 mg/kg followed by continuous infusion of 6 mg/kg/h, and alfentanil 15 micrograms/kg followed by continuous infusion of 15 micrograms/kg/h
Number of subjects: 40
Study 2108643 — intervention group
Group type: EXPERIMENTAL
Intervention: Anistreplase (30 units)
Number of subjects: 0
Study 444406 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy (cyclophosphamide, vincristine, adriamycin and 5‐fluorouracil)
Number of subjects: 72
Study 444406 — intervention group
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (oophorectomy, tamoxifen or androgens)
Number of subjects: 72
Study 444406 — intervention group
Group type: EXPERIMENTAL
Intervention: DNCB+ patients
Number of subjects: 72
Study 444406 — intervention group
Group type: EXPERIMENTAL
Intervention: Other tests (phytohaemagglutinin response, immunoglobulins G, A and M, or Mantoux test)
Number of subjects: 72
Study 444406 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 72
Study 31718737 — intervention group
Group type: EXPERIMENTAL
Intervention: Authentic Connections Virtual Groups (short-term intervention)
Number of subjects: 5
Study 31718737 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person version of Authentic Connections program (previous randomized trial)
Number of subjects: 5
Study 28052931 — intervention group
Group type: EXPERIMENTAL
Intervention: L.A.D.I.E.S. intervention
Number of subjects: 418
Study 28052931 — intervention group
Group type: COMPARATOR
Intervention: Faith-based program
Number of subjects: 418
Study 28052931 — intervention group
Group type: COMPARATOR
Intervention: Non-faith-based program
Number of subjects: 418
Study 28052931 — intervention group
Group type: COMPARATOR
Intervention: Self-guided program
Number of subjects: 418
Study 26001243 — intervention group
Group type: EXPERIMENTAL
Intervention: Gadoterate meglumine (0.1 mmol/kg)
Number of subjects: 189
Study 26001243 — intervention group
Group type: COMPARATOR
Intervention: Gadobutrol (0.1 mmol/kg)
Number of subjects: 189
Study 22902324 — intervention group
Group type: EXPERIMENTAL
Intervention: Allyl isothiocyanate (AITC)
Number of subjects: 46
Study 22902324 — intervention group
Group type: EXPERIMENTAL
Intervention: AITC-rich vegetables (M/C)
Number of subjects: 46
Study 22902324 — intervention group
Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 46
Study 20875219 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine-XR ≥ 300 mg/d
Number of subjects: 2864
Study 20875219 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine-XR (600 mg/d and 800 mg/d)
Number of subjects: 2864
Study 20875219 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2864
Study 19675115 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital video disk-based exercise programme (six exercise types, six levels of difficulty)
Number of subjects: 53
Study 19675115 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 53
Study 19675115 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital video disk-based exercise programme
Number of subjects: 53
Study 17166312 — intervention group
Group type: EXPERIMENTAL
Intervention: Early Training Group (ETG)
Number of subjects: 0
Study 17166312 — intervention group
Group type: COMPARATOR
Intervention: Late Training Group (LTG)
Number of subjects: 0
Study 15891649 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Interleaved Sampling (CIS)
Number of subjects: 25
Study 15891649 — intervention group
Group type: COMPARATOR
Intervention: Simultaneous Analog Stimulation (SAS)
Number of subjects: 25
Study 15891649 — intervention group
Group type: EXPERIMENTAL
Intervention: CIS
Number of subjects: 25
Study 15891649 — intervention group
Group type: COMPARATOR
Intervention: SAS
Number of subjects: 25
Study 11377314 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D sizing model
Number of subjects: 121
Study 11377314 — intervention group
Group type: COMPARATOR
Intervention: DRE estimates
Number of subjects: 121
Study 11377314 — intervention group
Group type: COMPARATOR
Intervention: Other scales
Number of subjects: 121
Study 9692075 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT (estradiol valerate (2 mg) plus cyproterone acetate, 1 mg, sequentially: ClimenR)
Number of subjects: 60
Study 9692075 — intervention group
Group type: EXPERIMENTAL
Intervention: HRT + Vit D (Climen + vitamin D3, 300 IU/day)
Number of subjects: 60
Study 9692075 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 women who refused all treatment)
Number of subjects: 60
Study 7925172 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (gamma‐vinyl GABA; VGB) as add-on therapy
Number of subjects: 73
Study 3294079 — intervention group
Group type: EXPERIMENTAL
Intervention: Garren-Edwards gastric bubble (bubble-sham)
Number of subjects: 90
Study 3294079 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment (sham-bubble)
Number of subjects: 90
Study 3294079 — intervention group
Group type: EXPERIMENTAL
Intervention: Garren-Edwards gastric bubble (bubble-bubble)
Number of subjects: 90
Study 31622569 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo position (KP)
Number of subjects: 44
Study 31622569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no KP)
Number of subjects: 44
Study 29452598 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment
Number of subjects: 115
Study 29452598 — intervention group
Group type: EXPERIMENTAL
Intervention: 14 days of antibiotic treatment
Number of subjects: 115
Study 28444396 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for at least 3 months
Number of subjects: 80
Study 28444396 — intervention group
Group type: COMPARATOR
Intervention: SDB patients (no CPAP treatment)
Number of subjects: 80
Study 26333879 — intervention group
Group type: EXPERIMENTAL
Intervention: Software-based self-testing system
Number of subjects: 40
Study 24134648 — intervention group
Group type: EXPERIMENTAL
Intervention: Low testosterone (LT) defined as TT <300 ng/dL
Number of subjects: 1896
Study 24134648 — intervention group
Group type: COMPARATOR
Intervention: Normal weight (BMI <25 kg/m(2))
Number of subjects: 1896
Study 24134648 — intervention group
Group type: COMPARATOR
Intervention: Overweight (BMI 25 to <30 kg/m(2))
Number of subjects: 1896
Study 24134648 — intervention group
Group type: COMPARATOR
Intervention: Obese (baseline BMI ≥30 kg/m(2))
Number of subjects: 1896
Study 21146458 — intervention group
Group type: EXPERIMENTAL
Intervention: Automation-assisted reading
Number of subjects: 73266
Study 21146458 — intervention group
Group type: COMPARATOR
Intervention: Manual reading
Number of subjects: 73266
Study 17765011 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep deprivation (55.5 and 58 hours of continuous wakefulness)
Number of subjects: 26
Study 17380830 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-assisted functional endoscopic sinus surgery (CASS)
Number of subjects: 95
Study 17380830 — intervention group
Group type: COMPARATOR
Intervention: Functional endoscopic sinus surgery (FESS) without computer assistance
Number of subjects: 95
Study 14967873 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g x d(‐1) Cr + 140 g x d(‐1) glucose for 7 days, followed by 5 g x d(‐1) Cr + 35 g x d(‐1) glucose for 21 days)
Number of subjects: 19
Study 14967873 — intervention group
Group type: COMPARATOR
Intervention: Placebo (160 g x d(‐1) glucose [loading] followed by 40 g x d(‐1) [maintenance])
Number of subjects: 19
Study 11092065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 2.50 mg
Number of subjects: 20
Study 11092065 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromocriptine 3.75 mg
Number of subjects: 20
Study 9112670 — intervention group
Group type: EXPERIMENTAL
Intervention: Iopromid/Ultravist‐300/Schering AG
Number of subjects: 82
Study 9112670 — intervention group
Group type: COMPARATOR
Intervention: Uropolinum, Polfa
Number of subjects: 82
Study 1519828 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 0.8 mg twice daily for 14 days
Number of subjects: 12
Study 1519828 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 6832199 — intervention group
Group type: EXPERIMENTAL
Intervention: Prajmalium bitartrate (PB) 80 mg/day for 4 days
Number of subjects: 13
Study 6832199 — intervention group
Group type: COMPARATOR
Intervention: Disopyramide 400 mg/day for 4 days
Number of subjects: 13
Study 30454846 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3mg and gabapentin 900mg
Number of subjects: 80
Study 30454846 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo capsule and gabapentin 900mg
Number of subjects: 80
Study 30266003 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone (XR-NTX)
Number of subjects: 37
Study 30266003 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study 27931305 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 U C1 INH with 24,000 U rHuPH20
Number of subjects: 47
Study 27931305 — intervention group
Group type: EXPERIMENTAL
Intervention: 2000 U C1 INH with 48,000 U rHuPH20
Number of subjects: 47
Study 24553190 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervarix®
Number of subjects: 91
Study 24553190 — intervention group
Group type: EXPERIMENTAL
Intervention: Gardasil®
Number of subjects: 91
Study 22265988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-fibre posts (GFP) with metal-ceramic (MC) crowns
Number of subjects: 50
Study 22265988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-fibre posts (GFP) with all-ceramic (AC) crowns
Number of subjects: 50
Study 22265988 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-fibre posts (GFP) with ferrule
Number of subjects: 50
Study 22265988 — intervention group
Group type: COMPARATOR
Intervention: Control group (intact ETC)
Number of subjects: 50
Study 20465990 — intervention group
Group type: EXPERIMENTAL
Intervention: Interceptor nets treated with alphacypermethrin 0.667% (200mg/m2)
Number of subjects: 19
Study 17353868 — intervention group
Group type: EXPERIMENTAL
Intervention: Supracervical laparoscopic hysterectomy (SLH)
Number of subjects: 141
Study 17353868 — intervention group
Group type: COMPARATOR
Intervention: Total laparoscopic hysterectomy (TLH)
Number of subjects: 141
Study 17353868 — intervention group
Group type: EXPERIMENTAL
Intervention: Both SLH and TLH
Number of subjects: 141
Study 17353868 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants weighing more than 100 kg
Number of subjects: 141
Study 16087941 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by TRT 63.0 Gy (arm 1, sequential)
Number of subjects: 0
Study 16087941 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction paclitaxel (200 mg/m2)/carboplatin (AUC = 6) followed by weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2) with concurrent TRT 63.0 Gy (arm 2, induction/concurrent)
Number of subjects: 0
Study 16087941 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (45 mg/m2)/carboplatin (AUC = 2)/TRT (63.0 Gy) followed by two cycles of paclitaxel (200 mg/m2)/carboplatin (AUC = 6; arm 3, concurrent/consolidation)
Number of subjects: 0
Study 16087941 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (arms 1 and 2)
Number of subjects: 0
Study 16087941 — intervention group
Group type: EXPERIMENTAL
Intervention: Concurrent chemoradiotherapy (arms 2 and 3)
Number of subjects: 0
Study 11583475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (0.5 mg/kg/day for the first 3 days, 0.25 mg/kg/day for the next 3 days, and 0.125 mg/kg/day for the 7th day)
Number of subjects: 50
Study 11583475 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Number of subjects: 50
Study 11583475 — intervention group
Group type: COMPARATOR
Intervention: Control (no dexamethasone)
Number of subjects: 50
Study 9826308 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan 200 mg IV
Number of subjects: 28
Study 9826308 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 7926327 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective dorsal rhizotomy (SDR) followed by one month of physical therapy at the center and a community physical therapy program
Number of subjects: 34
Study 7926327 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical therapy
Number of subjects: 34
Study 2688070 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg omeprazole once daily for 2 weeks
Number of subjects: 129
Study 2688070 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg omeprazole once daily for 4 weeks
Number of subjects: 129
Study 2688070 — intervention group
Group type: COMPARATOR
Intervention: Placebo after 2 weeks of healing
Number of subjects: 129
Study 2688070 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 129
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg) and Phenytoin (300 mg)
Number of subjects: 0
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbamazepine (1,200 mg) and Phenobarbital (300 mg)
Number of subjects: 0
Study 1106934 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (300 mg) and Phenobarbital (300 mg)
Number of subjects: 0